Skip to main content
Smart Investors Daily
VI

NASDAQ · VIR

Vir Biotechnology, Inc.

Healthcare · Biotechnology

$9.58

Down-$0.38 (-3.82%)

Updated Nov 17, 2026, 2:49 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
923.02M
P/E ratio
-1.67
Dividend yield
0.00%
52-week range
$5.45 – $14.38
Volume
6.78M
Avg. volume
1.53M

Price performance · VIR

VIR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

VIR closed at $9.58 after 21 trading sessions, down 6.17% for the selected period.

Last close
$9.58
Period change
-6.17%
Period low
$9.58
Period high
$13.65
Daily close
View OHLC price history
VIR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$9.85$10.04$9.57$9.586.78M
Nov 13, 2026$10.458$10.70$9.71$9.9616.66M
Nov 12, 2026$12.90$12.96$12.02$12.122.06M
Nov 11, 2026$13.22$13.43$12.9387$13.131.29M
Nov 10, 2026$13.66$13.74$13.105$13.151.3M
Nov 9, 2026$13.15$14.38$13.00$13.6457.12M
Nov 6, 2026$11.30$12.445$11.30$12.211.9M
Nov 5, 2026$11.92$12.16$10.98$11.022.93M
Nov 4, 2026$11.68$11.81$11.17$11.772.8M
Nov 3, 2026$11.10$11.38$11.10$11.221.55M
Nov 2, 2026$11.36$11.5454$11.00$11.001.38M
Oct 30, 2026$11.63$11.84$11.18$11.301.27M
Oct 29, 2026$11.69$12.19$11.55$11.751.42M
Oct 28, 2026$11.11$11.945$11.11$11.931.56M
Oct 27, 2026$11.00$11.63$10.86$11.571.97M
Oct 26, 2026$10.64$11.095$10.60$11.041.59M
Oct 23, 2026$10.36$10.59$10.03$10.571.69M
Oct 22, 2026$10.51$10.75$10.18$10.43987.07K
Oct 21, 2026$10.80$11.0244$10.55$10.571.14M
Oct 20, 2026$10.19$10.875$10.135$10.741.34M
Oct 19, 2026$10.035$10.295$9.96$10.211.31M

Latest VIR news

The latest Smart Investors Daily articles mentioning VIR.

VIR research

Overview

Company profile and research snapshot.

Company profile

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
VIR recent ratings
DateFirmRatingTarget
Nov 10, 2026Morgan StanleyOverweight—
Nov 10, 2026Evercore ISI GroupOutperform—
Nov 9, 2026NeedhamBuy—
Nov 9, 2026HC Wainwright & Co.Buy—
Nov 5, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.